pharma · Diabetes · Congenital Bleeding Disorder
Novo Nordisk A/S
Novo Nordisk A/S clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Novo Alle, Bagsværd, 2880, DK
- Founded
- 1923
- Employees
- 63,033
- Programs
- 40
- Drugs
- 46
- Patents
- 0
Novo Nordisk A/S projects
5 ClinicalTrials.gov programs sponsored by Novo Nordisk A/S.
Novo Nordisk A/S has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
LY2140023
Novo Nordisk A/S
Schizophrenia
1 trial -
Matched Placebo
Novo Nordisk A/S
Mechanical allodynia
1 trial -
NNC6019-0001
Novo Nordisk A/S
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
1 trial -
Product
Novo Nordisk A/S
Women with an indication for IVF/ICSI
1 trial -
activated recombinant human factor VII
Novo Nordisk A/S
Acquired Bleeding Disorder
2 trials
Frequently asked questions
How many clinical projects does Novo Nordisk A/S have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.